Perspective Therapeutics (CATX) Depreciation & Amortization (CF) (2010 - 2026)

Perspective Therapeutics has reported Depreciation & Amortization (CF) for 17 years, with the latest figure at $1.1 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 53.83% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.6 million (up 35.91% YoY) and the FY2025 annual result came in at $3.3 million, up 40.98% from the prior year.
• Depreciation & Amortization (CF) advanced to $1.1 million in Q1 2026 per CATX's latest filing, from $1.0 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $1.1 million in Q1 2026 and troughed at $74000.0 in Q1 2022.
• A 5-year average of $485117.6 and a median of $356000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) surged 276.92% in 2022, then climbed 15.84% in 2025.
• Over 5 years, Depreciation & Amortization (CF) stood at $138000.0 in 2022, then soared by 118.84% to $302000.0 in 2023, then jumped by 134.77% to $709000.0 in 2024, then jumped by 42.6% to $1.0 million in 2025, then gained by 11.37% to $1.1 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $1.1 million, $1.0 million, and $775000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.